- GlobeNewswire•5 days agoOncoMed Presents Initial First-in-Human Data for Anti-DLL4/VEGF Bispecific and Anti-RSPO3 at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Partial Responses and Stable Disease Achieved with Bispecific as a Single-Agent. Safety and Target Engagement Established for Anti-RSPO3. REDWOOD CITY, Calif., Nov. 29, 2016-- OncoMed Pharmaceuticals Inc. ...
- GlobeNewswire•12 days ago
REDWOOD CITY, Calif., Nov. 22, 2016-- OncoMed Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced ...
- GlobeNewswire•19 days agoOncoMed to Present Clinical Data for Anti-RSPO3 and Anti-DLL4/VEGF Bispecific Antibody at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
REDWOOD CITY, Calif., Nov. 15, 2016-- OncoMed Pharmaceuticals Inc. announced today it will present first-in-human data from its Phase 1 clinical trials of anti-RSPO3 and anti-DLL4/VEGF bispecific antibody ...
OMED : Summary for OncoMed Pharmaceuticals, Inc. - Yahoo Finance
OncoMed Pharmaceuticals, Inc. (OMED)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Day's Range||8.20 - 8.73|
|52 Week Range||8.07 - 23.98|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.50|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|